Despite concerted efforts at investigating and disseminating the health risks of tobacco dependence, millions of Americans continue to smoke chronically. Drug abusers have twice the smoking rate of the general population and suffer increasingly costly quality of life and health consequences. For example, more than 80% of opioid dependent individuals on buprenorphine maintenance therapy smoke cigarettes. Recent research suggests that cigarette smoking adversely affects brain morphology, blood flow, biochemistry, and cognition. These smoking-related brain abnormalities resemble those observed in chronic drug use and involve major components of the reward circuit, implicated in the initiation and maintenance of all forms of addiction. Tobacco dependence is also related to higher levels of non-nicotinic drug use after drug abuse treatment. The impact of combined opioid and tobacco dependence on neurobiology and behavior has not been evaluated systematically, and its relations to high smoking relapse rates in this population are poorly understood. Recent research implicates abnormalities in the reward circuitry as major contributor to relapse in all drug use, but corresponding evidence from opioid users in tobacco dependence treatment is lacking. The main purpose of this component is to a) obtain magnetic resonance-derived and neurocognitive measures of the integrity of frontal-subcortical brain circuits in opioid dependent individuals on buprenorphine replacement therapy before their extended, innovative tobacco dependence treatment, b) determine if these measures diffenentiate successful and unsuccessful quitters, and c) determine their ability to pnedlct obacco dependence treatment response at 3, 6, 12, and 18 months after treatment randomization. Exploratory genetic studies will address the influence of select single nucleotide polymorphisms on the main neurobiological and treatment outcome measures and the impact of these polymorphisms on quit rates. The overarching purpose of this research is to enable - within the existing framework of the Center - the development of a unique collaboration among two productive research teams at UCSF that both have aimed for many years to help reduce the overall impact of drug abuse on society. This multidisciplinary component, performed as part of a larger clinical trial of extended and innovative tobacco dependence treatment, is expected to increase our understanding of the extent to which neurobiological and cognitive deficiencies as well as specific genotypes contribute to an individual's ability to maintain long-term tobacco abstinence.

Public Health Relevance

Our experience in quantitative measurements of neurobiological and cognitive consequences of drug abuse supports the Center's mission to develop more efficacious tobacco dependence treatment for difficult to treat populations and to focus sparse treatment resources in long-term follow-up on those with more vulnerable phenotypes and genotypes. The proposal will inform on functionally and behaviorally relevant brain dysfunction in drug abuse in general. It complements other research proposed by this Center and provides useful information for public education, health policy, and prediction of treatment outcome.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Specialized Center (P50)
Project #
5P50DA009253-20
Application #
8668018
Study Section
Special Emphasis Panel (ZDA1-EXL-T)
Project Start
Project End
Budget Start
2014-06-01
Budget End
2015-05-31
Support Year
20
Fiscal Year
2014
Total Cost
$647,820
Indirect Cost
$27,118
Name
University of California San Francisco
Department
Type
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Pagano, Anna; Gubner, Noah R; Le, Thao et al. (2018) Differences in tobacco use prevalence, behaviors, and cessation services by race/ethnicity: A survey of persons in addiction treatment. J Subst Abuse Treat 94:9-17
Vogel, Erin A; Rubinstein, Mark L; Prochaska, Judith J et al. (2018) Associations between marijuana use and tobacco cessation outcomes in young adults. J Subst Abuse Treat 94:69-73
Murray, Donna E; Durazzo, Timothy C; Schmidt, Thomas P et al. (2018) Regional cerebral blood flow in opiate dependence relates to substance use and neuropsychological performance. Addict Biol 23:781-795
Schackman, Bruce R; Gutkind, Sarah; Morgan, Jake R et al. (2018) Cost-effectiveness of hepatitis C screening and treatment linkage intervention in US methadone maintenance treatment programs. Drug Alcohol Depend 185:411-420
Gubner, Noah R; Thrul, Johannes; Kelly, Oona A et al. (2018) Young adults report increased pleasure from smoking cigarettes when drinking alcohol but not when using marijuana. Addict Res Theory 26:71-76
Newville, Howard; Sorensen, James L; Hatch-Maillette, Mary et al. (2018) Temporal Relationship of Sex Risk Behaviors and Substance Use Severity Among Men in Substance Use Treatment. J Sex Res 55:1056-1064
Pagano, Anna; Gubner, Noah; Le, Thao et al. (2018) Cigarette smoking and quit attempts among Latinos in substance use disorder treatment. Am J Drug Alcohol Abuse 44:660-667
Guydish, Joseph; Tajima, Barbara; Le, Thao et al. (2018) Do cigarette graphic warnings encourage smokers to attend a smoking cessation programme: a quasi-experimental study. Tob Control 27:43-49
Gubner, Noah R; Guydish, Joseph; Humfleet, Gary L et al. (2017) Nicotine biomarkers and rate of nicotine metabolism among cigarette smokers taking buprenorphine for opioid dependency. Drug Alcohol Depend 178:267-270
McKnight, Courtney; Shumway, Martha; Masson, Carmen L et al. (2017) Perceived discrimination among racial and ethnic minority drug users and the association with health care utilization. J Ethn Subst Abuse 16:404-419

Showing the most recent 10 out of 337 publications